erlotinib has been researched along with pomalidomide in 1 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 623 | 121 | 552 |
| Protein | Taxonomy | erlotinib (IC50) | pomalidomide (IC50) |
|---|---|---|---|
| DNA damage-binding protein 1 | Homo sapiens (human) | 2.1 | |
| Protein cereblon | Homo sapiens (human) | 1.85 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bian, J; Li, L; Li, Z; Meng, Y; Wang, J; Xu, P; Xu, X | 1 |
1 other study(ies) available for erlotinib and pomalidomide
| Article | Year |
|---|---|
Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
Topics: Animals; Benzophenanthridines; Benzoquinones; Catalytic Domain; Cell Line, Tumor; Drug Discovery; Enzyme Inhibitors; Glutaminase; Humans; Mice; Molecular Docking Simulation; Protein Binding; Sulfides; Thiadiazoles; Thiazolidinediones | 2019 |